{"id":56164,"date":"2026-05-20T12:57:00","date_gmt":"2026-05-20T05:57:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=56164"},"modified":"2026-05-20T12:57:00","modified_gmt":"2026-05-20T05:57:00","slug":"hyundai-bioscience-able-to-supply-antiviral-drug-in-event-of-ebola-or-hantavirus-spread","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=56164","title":{"rendered":"Hyundai Bioscience: “Able to Supply Antiviral Drug in Event of Ebola or Hantavirus Spread”"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SEOUL, South Korea<\/span>, May 20, 2026<\/span> \/PRNewswire\/ — Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug\u00a0XAFTY\u00ae<\/sup> in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus.<\/p>\n

\n<\/div>\n

Hyundai Bioscience said that if the World Health Organization (WHO) or countries affected by infectious disease outbreaks request support for\u00a0XAFTY\u00ae<\/sup>, it can immediately provide products currently in stock.<\/p>\n

According to the company,\u00a0niclosamide, the main ingredient of XAFTY\u00ae<\/sup>, has previously been reported to have inhibitory effects against Ebola and hantavirus.<\/p>\n

The company stated, “In the ongoing Phase 2 clinical trial of\u00a0XAFTY\u00ae <\/sup>for dengue fever in Vietnam, no adverse events have been reported so far,” and claimed that “in a situation where two viruses are spreading simultaneously, XAFTY\u00ae <\/sup>could serve as an effective alternative.”<\/p>\n

Hyundai Bioscience added that, as a member of the Medical\u00a0CBRN Defense Consortium (MCDC), a U.S. Department of Defense-supported consortium, it will actively cooperate in responding to international public health crises.<\/p>\n

CONTACT\uff1a
Jason Kim
gbd@hyundaibio.com<\/a>
(562) 964-3910<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SEOUL, South Korea<\/span>, May 20, 2026<\/span> \/PRNewswire\/ — Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug\u00a0XAFTY\u00ae<\/sup> in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus.<\/p>\n

\n<\/div>\n

Hyundai Bioscience said that if the World Health Organization (WHO) or countries affected by infectious disease outbreaks request support for\u00a0XAFTY\u00ae<\/sup>, it can immediately provide products currently in stock.<\/p>\n

According to the company,\u00a0niclosamide, the main ingredient of XAFTY\u00ae<\/sup>, has previously been reported to have inhibitory effects against Ebola and hantavirus.<\/p>\n

The company stated, “In the ongoing Phase 2 clinical trial of\u00a0XAFTY\u00ae <\/sup>for dengue fever in Vietnam, no adverse events have been reported so far,” and claimed that “in a situation where two viruses are spreading simultaneously, XAFTY\u00ae <\/sup>could serve as an effective alternative.”<\/p>\n

Hyundai Bioscience added that, as a member of the Medical\u00a0CBRN Defense Consortium (MCDC), a U.S. Department of Defense-supported consortium, it will actively cooperate in responding to international public health crises.<\/p>\n

CONTACT\uff1a
Jason Kim
gbd@hyundaibio.com<\/a>
(562) 964-3910<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-56164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/56164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56164"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/56164\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}